Nuvectis Pharma, Inc. ((NVCT)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nuvectis Pharma, Inc. is currently conducting a Phase 1 clinical study titled ‘A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of NXP900 in patients with advanced solid tumors, including those with specific genetic alterations. This research is significant as it targets genetic pathways that could offer new treatment options for difficult-to-treat cancers.
The intervention being tested is NXP900, an orally administered SRC/YES1 kinase inhibitor. This drug is designed to target specific genetic alterations in cancer cells, potentially inhibiting tumor growth and progression.
The study is interventional and follows a non-randomized, sequential assignment model. It involves dose escalation and expansion phases, with no masking involved. The primary purpose of the study is treatment-focused, aiming to determine the optimal dose and assess the drug’s impact on cancer progression.
The study began on May 15, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on August 15, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates.
This clinical update could influence Nuvectis Pharma’s stock performance and investor sentiment, as successful outcomes may enhance the company’s market position. Investors should also consider the competitive landscape, as advancements in cancer treatment are highly sought after in the pharmaceutical industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.